Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs. clindamycin 1% lotion in mild-to-moderate truncal acne: an open-label randomized controlled clinical trial
Clinical and Experimental Dermatology · 2026-08-28
DOI: 10.1093/ced/llag372 ↗Abstract
Abstract Background Truncal acne is a frequently encountered but relatively understudied manifestation of acne vulgaris and is often associated with significant physical discomfort and psychosocial impact. Topical clindamycin has been used extensively in mild-to-moderate acne; however, there are concerns regarding antimicrobial resistance, which has prompted interest in alternative topical agents. Ozenoxacin, a nonfluorinated quinolone, offers broad-spectrum antibacterial activity with minimal systemic absorption. Objectives To compare the effectiveness, safety and tolerability of ozenoxacin 2% lotion with clindamycin 1% lotion in patients with mild-to-moderate truncal acne. Methods This institution-based, open-label, randomized controlled trial (registered with the Clinical Trials Registry of India: CTRI/2025/02/080133) included 78 patients aged 18–35 years with mild-to-moderate truncal acne. Participants were randomized to receive either ozenoxacin 2% lotion or clindamycin 1% lotion applied twice daily for 12 weeks. Both groups received adapalene 0.1% gel for once-daily application at bedtime. Clinical efficacy and quality of life were assessed using total, inflammatory and noninflammatory lesion counts, and the Investigator Global Assessment, Cardiff Acne Disability Index and Dermatology Life Quality Index scores. Safety was evaluated through adverse event monitoring. Results Thirty-five patients in the ozenoxacin group and 34 in the clindamycin group completed the study. Both groups demonstrated statistically significant improvement from baseline in all efficacy parameters at 12 weeks (P < 0.05). Intergroup comparisons showed no statistically significant differences across clinical or quality-of-life outcomes. Both treatments were well tolerated, with only mild and transient adverse effects reported. Conclusions Ozenoxacin demonstrated comparable efficacy and tolerability to clindamycin when used in combination with adapalene in truncal acne.
EUVIMED